MTNB Matinas BioPharma Holdings Inc. Total Asset Value of Company

The asset value for Matinas BioPharma (MTNB) tracked on the chart is 7.42, based on the use of unique lipid crystals for oral drug delivery via B2B contracts. Matinas BioPharma is implementing automated software and robotics to analyze clinical data sets for oligonucleotides. The development strategy relies on the monetization of patents for increasing drug bioavailability through a royalty system.

Given the necessity of maintaining strategic reserves of lipid nanocrystals to ensure supply stability, the trajectory of total assets (via ROA) reflects the actual scale of Matinas BioPharma resources, reverse-calculated as the sum of liabilities and equity through return on assets, allowing the investor to assess the business's actual material base and its resilience to macroeconomic shocks without the risk of excessive debt load.